Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22863196 | 1.00 | ACHE (0.42) | ACHEPTGS2ALDH1A1TSHRTDP1 | |
| SCHEMBL20165703 | 1.00 | ACHE (0.42) | ACHEPTGS2ALDH1A1TSHRTDP1 | |
| SCHEMBL27433076 | 0.91 | ACHE (0.45) | ACHEPTGS2ALDH1A1TSHRTDP1 | |
| SCHEMBL14645803 | 0.88 | ACHE (0.42) | ACHEPTGS2 | |
| SCHEMBL14645764 | 0.85 | ACHE (0.45) | ACHE | |
| SCHEMBL27432437 | 0.85 | ACHE (0.42) | ACHEPTGS2ALDH1A1TSHRTDP1 | |
| SCHEMBL31342804 | 0.85 | — | — | |
| SCHEMBL20165758 | 0.85 | ACHE (0.40) | ACHEPTGS2 | |
| SCHEMBL31355494 | 0.85 | CNR2 (0.33) | CNR2 | |
| SCHEMBL21451184 | 0.85 | CNR2 (0.33) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682201-A1 | BETA-NUCLEATED MULTIMODAL COPOLYMERS | Borealis GmbH (AT) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025051400-A1 | METHODS OF PRODUCING METALLOCENE CATALYST COMPONENTS | BOREALIS AG (AT) | 2025-03-13 | — | — | WO | disclosed |
| EP-3820939-B1 | HETEROPHASIC POLYPROPYLENE COMPOSITION WITH IMPROVED BALANCE OF PROPERTIES | BOREALIS AG (AT) | 2024-06-05 | — | — | EP | disclosed |
| US-11952481-B2 | Heterophasic polypropylene composition with high flexibility and softness | BOREALIS AG (AT) | 2024-04-09 | — | — | US | disclosed |
| CN-111527140-B | Heterophasic polypropylene composition with high flexibility and high softness | 北欧化工公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11807655-B2 | Catalysts | BOREALIS AG (AT) | 2023-11-07 | — | — | US | disclosed |
| US-11807655-B2 | Catalysts | BOREALIS AG (AT) | 2023-11-07 | — | — | US | disclosed |
| US-11807655-B2 | Catalysts | BOREALIS AG (AT) | 2023-11-07 | — | — | US | disclosed |
| CN-113474406-B | Nucleated propylene polymer compositions with high toughness | 博里利斯股份公司 | 2023-09-15 | — | — | CN | disclosed |
| US-11702487-B2 | Process for preparing propylene polymers | BOREALIS AG (AT) | 2023-07-18 | — | — | US | disclosed |
| WO-2019179959-A1 | CATALYSTS FOR OLEFIN POLYMERIZATION | BOREALIS AG (AT) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019141546-A1 | HETEROPHASIC POLYPROPYLENE COMPOSITION WITH HIGH FLEXIBILITY AND SOFTNESS | BOREALIS AG (AT) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019052820-A1 | POLYPROPYLENE COMPOSITION | BOREALIS AG (AT) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019052820-A1 | POLYPROPYLENE COMPOSITION | BOREALIS AG (AT) | 2019-03-21 | — | — | WO | disclosed |
| EP-3456776-A1 | POLYPROPYLENE COMPOSITION | Borealis AG (AT) | 2019-03-20 | — | — | EP | disclosed |
| EP-3456776-A1 | POLYPROPYLENE COMPOSITION | Borealis AG (AT) | 2019-03-20 | — | — | EP | disclosed |
| WO-2019007655-A1 | PROCESS FOR PREPARING HETEROPHASIC PROPYLENE COPOLYMERS | BOREALIS AG (AT) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019007655-A1 | PROCESS FOR PREPARING HETEROPHASIC PROPYLENE COPOLYMERS | BOREALIS AG (AT) | 2019-01-10 | — | — | WO | disclosed |
| WO-2018122134-A1 | CATALYSTS | BOREALIS AG (AT) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018091684-A1 | CATALYSTS | BOREALIS AG (AT) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807655-B2 | Catalysts | SOD1, MT-CO2, MT-CO1 | ACHE 3437/4885PTGS2 2491/4885ALDH1A1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.